SCHEMBL1312943

SCHEMBL1312943

CC(N)CC(O)c1cccs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.44
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
KMT2A Q03164 2/20 0.42
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
KEAP1 Q14145 1/20 0.40
SLC5A2 P31639 1/20 0.38
HTR1A P08908 2/20 0.37
TSHR P16473 1/20 0.37
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP3A4 P08684 3/20 0.35
CYP2D6 P10635 3/20 0.35
SLC6A2 P23975 3/20 0.35
SLC6A4 P31645 3/20 0.35
SLC6A3 Q01959 3/20 0.35
KCNH2 Q12809 3/20 0.35
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19830553 0.85 NPC1 (0.44) ALOX5RAB9ANPC1KMT2ACES2
SCHEMBL15765746 0.81 ALOX5 (0.42) ALOX5RAB9ANPC1KMT2ACES2
SCHEMBL4622045 0.81 NPC1 (0.39) ALOX5RAB9ANPC1KMT2ACES2
SCHEMBL27612380 0.79 LMNA (0.39) ALOX5RAB9ANPC1KMT2ASLC5A2
SCHEMBL1535344 0.79 RAB9A (0.40) ALOX5RAB9ANPC1KMT2ACES2
Methylamine SCHEMBL28554106 0.77 NPC1 (0.44) ALOX5RAB9ANPC1KMT2ACES2
SCHEMBL6236376 0.76 NPC1 (0.41) ALOX5RAB9ANPC1KMT2ACES2
SCHEMBL7296321 0.76
SCHEMBL2849489 0.76
SCHEMBL1232757 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8269023-B2 Process for preparation of duloxetine hydrochloride LUPIN LTD. (IN) 2012-09-18 US claimed
US-20110275835-A1 PROCESS FOR PREPARING (S)-(+)-N-METHYL-3-(1-NAPHTHYLOXY)-3-(2-THIENYL)PROPYLAMINE BY USING OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL COMPOUND AS INTERMEDIATE SCI PHARMTECH, INC. (TW) 2011-11-10 US claimed
US-20100105925-A1 NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE LUPIN LIMITED (IN) 2010-04-29 US claimed
EP-2132192-A2 NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE Lupin Limited (IN) 2009-12-16 EP claimed
WO-2008107911-A2 NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE LUPIN LIMITED (IN) 2008-09-12 WO claimed
EP-2132192-B1 NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE LUPIN LTD (IN) 2013-04-24 EP disclosed
US-8269023-B2 Process for preparation of duloxetine hydrochloride LUPIN LTD. (IN) 2012-09-18 US disclosed
US-20100105925-A1 NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE LUPIN LIMITED (IN) 2010-04-29 US disclosed
WO-2010025287-A2 KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE CODEXIS, INC. (US) 2010-03-04 WO disclosed
EP-2132192-A2 NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE Lupin Limited (IN) 2009-12-16 EP disclosed
CN-101337958-A Process for preparing 3-methylamino-1- (2-thienyl) -1-propanol compounds ZHEJIANG LIAOYUAN PHARMACEUTIC (CN) 2009-01-07 CN disclosed
US-7435563-B2 Method for the production of (s)-3-methylamino-1-(thien-2-yl)propan-1-ol BASF AKTIENGESELLSCHAFT (DE) 2008-10-14 US disclosed
US-7435563-B2 Method for the production of (s)-3-methylamino-1-(thien-2-yl)propan-1-ol BASF AKTIENGESELLSCHAFT (DE) 2008-10-14 US disclosed
WO-2008107911-A2 NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE LUPIN LIMITED (IN) 2008-09-12 WO disclosed
EP-1789385-A1 METHOD FOR PRODUCING N-ALKYL-N-METHYL-3-HYDROXY-3-(2-THIENYL)-PROPYLAMINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-30 EP disclosed
US-20050245749-A1 Method for the production of (s)-3-methylamino-1-(thien-2-yl)propan-1-ol BASF AKTIENGESELLSCHAFT (DE) 2005-11-03 US disclosed
US-20050245749-A1 Method for the production of (s)-3-methylamino-1-(thien-2-yl)propan-1-ol BASF AKTIENGESELLSCHAFT (DE) 2005-11-03 US disclosed
WO-2005085192-A1 METHOD FOR PRODUCING N-ALKYL-N-METHYL-3-HYDROXY-3-(2-THIENYL)-PROPYLAMINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245749-A1 Method for the production of (s)-3-methylamino-1-(thien-2-yl)propan-1-ol INMT, PNMT, TH ALOX5 1531/4885RAB9A 4672/4885NPC1 3649/4885
US-20110275835-A1 PROCESS FOR PREPARING (S)-(+)-N-METHYL-3-(1-NAPHTHYLOXY)-3-(2-THIENYL)PROPYLAMINE BY USING OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL COMPOUND AS INTERMEDIATE PNMT, HNMT, INMT ALOX5 546/4885RAB9A 4113/4885NPC1 859/4885
US-20100105925-A1 NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE MAOA, SLC6A3, PNMT ALOX5 3276/4885RAB9A 1260/4885NPC1 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.